Trevi Therapeutics initiates OCEAN-1 Phase 3 and LAKE Phase 2b trials for chronic cough

Trevi Therapeutics (NASDAQ: TRVI) initiated the OCEAN-1 Phase 3 trial and the LAKE Phase 2b trial for chronic cough, with plans to start the OCEAN-2 Phase 3 trial in Q3 2026. The company ended Q2 2026 with $319 million in cash, extending its runway into 2030.

Detected & updated continuously · Source: Nebula